mTOR Signaling in Metabolism and Cancer
The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in thi...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (204 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993546103704498 |
|---|---|
| ctrlnum |
(CKB)5400000000040975 (oapen)https://directory.doabooks.org/handle/20.500.12854/69370 (EXLCZ)995400000000040975 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Huang, Shile edt mTOR Signaling in Metabolism and Cancer Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (204 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases. English Medicine bicssc mTOR histone deacetylase prostate cancer integrins adhesion invasion cell metabolism T cells Foxp3 Acute Lymphoblastic leukemia targeted therapy metabolism cell signalling mTOR signalling head and neck cancer mutant genes biomarkers targeted therapies clinical trials cancers inhibitors photodynamic therapy PI3K Akt skin cancers phytochemicals melanoma basal cell carcinoma squamous cell carcinoma Merkel cell carcinoma TNBC eribulin PI3K/AKT/mTOR everolimus combination synergy mTOR signaling tissue regeneration neuron muscle liver intestine hematologic malignancies regulatory T cells tumor 3-03943-553-1 3-03943-554-X Huang, Shile oth |
| language |
English |
| format |
eBook |
| author2 |
Huang, Shile |
| author_facet |
Huang, Shile |
| author2_variant |
s h sh |
| author2_role |
Sonstige |
| title |
mTOR Signaling in Metabolism and Cancer |
| spellingShingle |
mTOR Signaling in Metabolism and Cancer |
| title_full |
mTOR Signaling in Metabolism and Cancer |
| title_fullStr |
mTOR Signaling in Metabolism and Cancer |
| title_full_unstemmed |
mTOR Signaling in Metabolism and Cancer |
| title_auth |
mTOR Signaling in Metabolism and Cancer |
| title_new |
mTOR Signaling in Metabolism and Cancer |
| title_sort |
mtor signaling in metabolism and cancer |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2020 |
| physical |
1 electronic resource (204 p.) |
| isbn |
3-03943-553-1 3-03943-554-X |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT huangshile mtorsignalinginmetabolismandcancer |
| status_str |
n |
| ids_txt_mv |
(CKB)5400000000040975 (oapen)https://directory.doabooks.org/handle/20.500.12854/69370 (EXLCZ)995400000000040975 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
mTOR Signaling in Metabolism and Cancer |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1796648776985739264 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02902nam-a2200829z--4500</leader><controlfield tag="001">993546103704498</controlfield><controlfield tag="005">20231214132928.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040975</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69370</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040975</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Huang, Shile</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">mTOR Signaling in Metabolism and Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (204 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">histone deacetylase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">integrins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adhesion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">invasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Foxp3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Acute Lymphoblastic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell signalling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR signalling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutant genes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photodynamic therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Akt</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">skin cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phytochemicals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">basal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">squamous cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Merkel cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNBC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eribulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K/AKT/mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">everolimus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synergy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tissue regeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuron</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">muscle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intestine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hematologic malignancies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-553-1</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-554-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Shile</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:36:07 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338113670004498&Force_direct=true</subfield><subfield code="Z">5338113670004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338113670004498</subfield></datafield></record></collection> |